Every material Form 8-K Corbus Pharmaceuticals Holdings, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 15, 2026, Corbus Pharmaceuticals filed an 8-K furnishing an updated corporate presentation that management uses to describe its business. The presentation covers early clinical data for its CRB-701 cancer drug and CRB-913 obesity drug, but it contains no new financial results or guidance, and the filing is furnished rather than filed.
Cash, cash equivalents and investments were $118 million as of June 30, 2026, per the presentation.
CRB-701 first patient was dosed in the registrational TEMPO-1 study in September 2026; topline data in first-line OPSCC expected in Q1 2027.
CRB-913 Phase 1b CANYON-1 study (254 patients) showed 5% placebo-adjusted weight loss at 12 weeks on the 60mg dose; Phase 2 expected to start in 1H 2027.
About 18.7 million common shares were outstanding (about 22.4 million fully diluted).
Corbus Pharmaceuticals announced positive topline results from its 16-week CANYON-1 Phase 1b trial of oral CRB-913 for obesity, showing statistically significant weight loss at all three doses, with the 60 mg dose producing a mean 5.0% weight loss at 12 weeks versus placebo. The data will be presented as a late-breaking abstract at ObesityWeek 2026, and the company plans to engage with the FDA and start a Phase 2 monotherapy study in the first half of 2027. The filing reports no revenue or profit figures, and the results come from a small early-stage trial with cross-trial safety comparisons that the company itself notes are not head-to-head.
60 mg cohort (n=62) showed 5.0% mean weight loss at week 12 versus 0.0% for placebo (n=66), p<0.0001
Treatment discontinuations due to adverse events were 3.1% to 13.1% for CRB-913, versus 6.9% to 20.7% for approved oral GLP-1 drugs, per cross-trial comparison
Data to be presented at ObesityWeek 2026, November 14 to 17, 2026; Phase 2 monotherapy study expected to start in first half of 2027
Corbus Pharmaceuticals reported a second-quarter 2026 net loss of $35.0 million, or $1.81 per share, up from $17.7 million, or $1.44 per share, a year earlier, as operating expenses rose to $36.2 million. The company said it had $117.9 million in cash, cash equivalents and investments at June 30, 2026, expected to fund operations into 2028, and it announced new executive and board appointments. Shareholders face a larger loss and a higher expense base while the company's two key clinical milestones are expected in September 2026.
Net loss of $35.0 million, or $1.81 per share, for the quarter ended June 30, 2026, versus $17.7 million, or $1.44 per share, a year earlier
Operating expenses of $36.2 million, up from $19.2 million, including a $10.0 million development milestone payment for CRB-701
Cash, cash equivalents and investments of $117.9 million at June 30, 2026, expected to fund operations into 2028
CANYON-1 Phase 1b topline data for CRB-913 in obesity and TEMPO-1 enrollment both expected in September 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Corbus Pharmaceuticals Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →